eMedicine Specialties > Emergency Medicine > Toxicology

Toxicity, Antidepressant: Differential Diagnoses & Workup

Author: Jeena Jacob, MD, PharmD, Resident Physician, Department of Emergency Medicine, Yale-New Haven Hospital
Contributor Information and Disclosures

Updated: Nov 13, 2008

Differential Diagnoses

Alcoholic Ketoacidosis
Toxicity, Anticholinergic
Anaphylaxis
Toxicity, Antidysrhythmic
Anxiety
Toxicity, Antihistamine
Delirium Tremens
Toxicity, Beta-blocker
Heart Block, First Degree
Toxicity, Calcium Channel Blocker
Heart Block, Second Degree
Toxicity, Clonidine
Heart Block, Third Degree
Toxicity, CNS depressants
Hyperkalemia
Toxicity, Cocaine
Hyperosmolar Hyperglycemic Nonketotic Coma
Toxicity, Digitalis
Neuroleptic Malignant Syndrome
Toxicity, Isoniazid
Pediatrics, Reye Syndrome
Toxicity, Monoamine Oxidase Inhibitor
Serotonin Syndrome
Toxicity, Neuroleptic Agents
Shock, Cardiogenic
Toxicity, Phencyclidine
Shock, Septic
Withdrawal, ethanol, benzodiazepines, barbiturates
Subarachnoid Hemorrhage
Subdural Hematoma

Other Problems to Be Considered

Antimalarial toxicity (eg, chloroquine, primaquine)
Chloral hydrate toxicity
Intrinsic cardiac disease (other causes of conduction disturbances, dysrhythmias, hypotension)
Intrinsic neurologic disease (other causes of seizures, altered mental status)

Workup

Laboratory Studies

  • Quantitative screening or tricyclic serum concentrations are of minimal utility in the acute setting because serum levels do not correlate with acute toxicity secondary to pharmacologic properties such as large volume of distribution, pH-dependent protein binding, wide intrapatient variability of terminal elimination half-lives, and prolonged distribution phases. A toxicology screen may be helpful if concurrent ingestion is possible or if symptoms are not fully explained by tricyclic antidepressants (TCAs). An abbreviated screen for acetaminophen and aspirin coingestants usually is sufficient. 
  • Electrolytes and glucose levels should be used to screen for anion gap acidosis that exists with other ingestions and to look for metabolic disturbances that can alter mental status, cause seizures, or change the ECG.
  • Serum pH
    • Blood gas analysis should be obtained to check pH with an attempt to maintain an alkaline environment (pH = 7.45-7.55).
    • Acidemia allows a greater degree of fast sodium channel binding by the TCA and produces a wider QRS on the ECG.

Imaging Studies

  • Obtain a chest radiograph after intubation or if evidence of hypoxia, aspiration, or ARDS is present.

Other Tests

An ECG has great utility in predicting the severity of toxicity.

  • ECG is the single most important test to determine diagnosis and prognosis.
  • Several studies have shown that a QRS duration greater than 100 milliseconds on an ECG is associated with an increased incidence of seizures, coma, need for intubation, hypotension, and dysrhythmias.  
  • Prospective studies of patients with TCA overdose show that the sensitivity of an R-wave greater than 3 mm in aVR is similar to the sensitivity of a QRS=100 msec. Prospective data suggest that the typical period of QRS prolongation after severe tricyclic antidepressant ingestion is 12-18 hours but may be as long as 3 days. 
  • Rightward deviation of QRS vector (a negative deflection in lead 1 and a positive final deflection in lead aVR) is associated with TCA toxicity.
  • Sinus tachycardia is a typical but nonspecific early sign of TCA toxicity.
  • Case reports have described ECGs in TCA toxicity mimicking acute myocardial infarction and the Brugada syndrome. One study found that 17% of patients that presented with TCA poisoning and ECG changes had Brugada pattern on ECG, which is a manifestation of intraventricular conduction disturbances.
  • Dysrhythmias are also nonspecific to TCA toxicity but important to respond to.
    • Ventricular tachycardia is the most common lethal dysrhythmia.
    • Torsade de pointes is uncommon in overdose but may occur in patients taking therapeutic doses.
  • Bradycardia and asystole are usually preterminal rhythms, although patients have been resuscitated from these with aggressive supportive care.

Procedures

  • Endotracheal intubation
    • Aggressively manage airway for patients who present agitated or with a decreased level of consciousness. For these patients, endotracheal intubation may be required before gastric lavage or activated charcoal to prevent aspiration.
    • The patient should be hyperventilated after intubation. Check proper placement with a chest radiograph. The target PaCO2 is 30 mm Hg by ABG following intubation.
  • Gastric lavage
    • After the patient's airway, breathing, and circulation are secured, gastric lavage can be initiated in the symptomatic patient with an intentional overdose within 1.5-2 hours after ingestion.
    • If the patient exhibits declining mental status, the intubation should be performed first. Activated charcoal should be administered if the benefit of charcoal administration outweighs the risk of aspiration.
  • A central venous line may be helpful in administering medication and monitoring fluid status.
  • Hemodialysis
    • Hemodialysis and hemoperfusion are not effective and are not recommended for TCA poisoning.
    • The poor efficacy of hemodialysis probably is because only a small amount of free TCA is present in the serum. TCA is highly bound to serum proteins and tissues, with a large volume of distribution.
  • Only anecdotal evidence supports the efficacy of an intra-aortic balloon pump (IABP) for intractable hypotension.

More on Toxicity, Antidepressant

Overview: Toxicity, Antidepressant
Differential Diagnoses & Workup: Toxicity, Antidepressant
Treatment & Medication: Toxicity, Antidepressant
Follow-up: Toxicity, Antidepressant
Multimedia: Toxicity, Antidepressant
References

References

  1. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila). Dec 2007;45(8):815-917. [Medline][Full Text].

  2. Heard K, Dart RC, Bogdan G, et al. A preliminary study of tricyclic antidepressant (TCA) ovine FAB for TCA toxicity. Clin Toxicol (Phila). 2006;44(3):275-81. [Medline].

  3. Bailey B, Buckley NA, Amre DK. A meta-analysis of prognostic indicators to predict seizures, arrhythmias or death after tricyclic antidepressant overdose. J Toxicol Clin Toxicol. 2004;42(6):877-88. [Medline].

  4. Barry JD, Durkovich DW, Williams SR. Vasopressin treatment for cyclic antidepressant overdose. J Emerg Med. Jul 2006;31(1):65-8. [Medline].

  5. Bebarta VS, Phillips S, Eberhardt A, et al. Incidence of Brugada electrocardiographic pattern and outcomes of these patients after intentional tricyclic antidepressant ingestion. Am J Cardiol. Aug 15 2007;100(4):656-60. [Medline].

  6. Fletcher SE, Case CL, Sallee FR, et al. Prospective study of the electrocardiographic effects of imipramine in children. J Pediatr. Apr 1993;122(4):652-4. [Medline].

  7. Graudins A, Dowsett RP, Liddle C. The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants. Emerg Med (Fremantle). Dec 2002;14(4):440-6. [Medline].

  8. Høegholm A, Clementsen P. Hypertonic sodium chloride in severe antidepressant overdosage. J Toxicol Clin Toxicol. 1991;29(2):297-8. [Medline].

  9. Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. Aug 1995;26(2):195-201. [Medline].

  10. Liebelt EL, Ulrich A, Francis PD, et al. Serial electrocardiogram changes in acute tricyclic antidepressant overdoses. Crit Care Med. Oct 1997;25(10):1721-6. [Medline].

  11. McCabe JL, Cobaugh DJ, Menegazzi JJ, et al. Experimental tricyclic antidepressant toxicity: a randomized, controlled comparison of hypertonic saline solution, sodium bicarbonate, and hyperventilation. Ann Emerg Med. Sep 1998;32(3 Pt 1):329-33. [Medline].

  12. McKenzie MS, McFarland BH. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf. May 2007;16(5):513-23. [Medline].

  13. McKinney PE, Rasmussen R. Reversal of severe tricyclic antidepressant-induced cardiotoxicity with intravenous hypertonic saline solution. Ann Emerg Med. Jul 2003;42(1):20-4. [Medline].

  14. Monteban-Kooistra WE, van den Berg MP, Tulleken JE, et al. Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. Intensive Care Med. Feb 2006;32(2):281-5. [Medline].

  15. Obrador D, Ballester M, Carrio I, et al. Presence, evolving changes, and prognostic implications of myocardial damage detected in idiopathic and alcoholic dilated cardiomyopathy by 111In monoclonal antimyosin antibodies. Circulation. May 1994;89(5):2054-61. [Medline].

  16. Svens K, Ryrfeldt A. A study of mechanisms underlying amitriptyline-induced acute lung function impairment. Toxicol Appl Pharmacol. Dec 15 2001;177(3):179-87. [Medline].

  17. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning : cardiovascular toxicity. Toxicol Rev. 2005;24(3):205-14. [Medline].

  18. Tran TP, Panacek EA, Rhee KJ, et al. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension. Acad Emerg Med. Sep 1997;4(9):864-8. [Medline].

  19. Woolf AD, Erdman AR, Nelson LS, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-33. [Medline].

  20. Zuidema X, Dünser MW, Wenzel V, et al. Terlipressin as an adjunct vasopressor in refractory hypotension after tricyclic antidepressant intoxication. Resuscitation. Feb 2007;72(2):319-23. [Medline].

Further Reading

Keywords

antidepressant toxicity, antidepressant overdose, tricyclic antidepressants, TCAs, cyclic antidepressants, antidepressant poisoning, TCA toxicity, TCA overdose, TCA exposure, treatment of depression

Contributor Information and Disclosures

Author

Jeena Jacob, MD, PharmD, Resident Physician, Department of Emergency Medicine, Yale-New Haven Hospital
Jeena Jacob, MD, PharmD is a member of the following medical societies: American Medical Association, Emergency Medicine Residents Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

David C Lee, MD, Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School
David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals
John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.

Managing Editor

Michael J Burns, MD, Instructor, Department of Emergency Medicine, Harvard University Medical School, Beth Israel Deaconess Medical Center
Michael J Burns, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD, Assistant Professor, Department of Surgery, Section of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.